ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImageneBio (Nasdaq: IMA), a clinical stage biotech company focused on immunological and inflammatory diseases, has granted significant inducement equity awards to its new CEO, Dr. Kristin Yarema. The compensation package includes 436,080 stock options at an exercise price of $16.37 per share and 153,505 restricted stock units (RSUs).
The awards, granted on July 28, 2025, feature a four-year vesting schedule with 25% vesting after one year and the remaining 75% vesting over subsequent periods. The stock options have a ten-year term, while RSUs will vest quarterly after the initial one-year cliff. All awards are contingent on Dr. Yarema's continued service with the company.
ImageneBio (Nasdaq: IMA), una societ脿 biotech in fase clinica specializzata in malattie immunologiche e infiammatorie, ha assegnato importanti premi azionari di incentivazione alla sua nuova CEO, Dr.ssa Kristin Yarema. Il pacchetto retributivo comprende 436.080 opzioni su azioni con un prezzo di esercizio di $16,37 per azione e 153.505 unit脿 azionarie vincolate (RSU).
I premi, concessi il 28 luglio 2025, prevedono un piano di maturazione quadriennale con il 25% che matura dopo un anno e il restante 75% che matura nei periodi successivi. Le opzioni azionarie hanno una durata di dieci anni, mentre le RSU maturano trimestralmente dopo il primo anno di attesa. Tutti i premi sono subordinati alla permanenza della Dr.ssa Yarema in azienda.
ImageneBio (Nasdaq: IMA), una empresa biotecnol贸gica en etapa cl铆nica enfocada en enfermedades inmunol贸gicas e inflamatorias, ha otorgado importantes premios de acciones inducidas a su nueva CEO, Dra. Kristin Yarema. El paquete de compensaci贸n incluye 436,080 opciones sobre acciones con un precio de ejercicio de $16.37 por acci贸n y 153,505 unidades de acciones restringidas (RSU).
Los premios, otorgados el 28 de julio de 2025, cuentan con un calendario de adquisici贸n de derechos de cuatro a帽os, con un 25% que se adquiere despu茅s de un a帽o y el 75% restante en per铆odos posteriores. Las opciones sobre acciones tienen un plazo de diez a帽os, mientras que las RSU se adquieren trimestralmente despu茅s del primer a帽o de espera. Todos los premios dependen del servicio continuo de la Dra. Yarema en la empresa.
ImageneBio (雮橃姢雼�: IMA)電� 氅挫棴 氚� 鞐检 歆堩櫂鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厤 須岇偓搿�, 靸堧鞖� CEO鞚� Dr. Kristin Yarema鞐愱矊 靸侂嫻頃� 鞙犾澑 欤检嫕 氤挫儊鞚� 攵�鞐枅鞀惦媹雼�. 氤挫儊 韺偆歆�鞐愲姅 欤茧嫻 $16.37鞚� 頄夓偓 臧�瓴╈溂搿� 436,080 欤检嫕 鞓奠厴瓿� 153,505 鞝滍暅 欤检嫕 雼渼(RSU)臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
鞚� 氤挫儊鞚� 2025雲� 7鞗� 28鞚�鞐� 攵�鞐悩鞐堨溂氅�, 4雲勱皠鞚� 甓岆Μ 旆摑 鞚检爼鞚� 鞝侅毄霅橃柎 1雲� 頉� 25%臧� 旆摑霅橁碃 雮橂ǜ歆� 75%電� 鞚错泟 旮瓣皠鞐� 瓯胳硱 旆摑霅╇媹雼�. 欤检嫕 鞓奠厴鞚� 10雲勳潣 毵岅赴毳� 臧�歆�氅�, RSU電� 齑堦赴 1雲� 雽�旮� 旮瓣皠 頉� 攵勱赴氤勲 旆摑霅╇媹雼�. 氇摖 氤挫儊鞚� Dr. Yarema臧� 須岇偓鞐� 瓿勳啀 攴茧頃橂姅 瓴冹潉 臁瓣贝鞙茧 頃╇媹雼�.
ImageneBio (Nasdaq : IMA), une soci茅t茅 biotechnologique en phase clinique sp茅cialis茅e dans les maladies immunologiques et inflammatoires, a accord茅 des r茅compenses en actions incitatives importantes 脿 sa nouvelle PDG, Dr Kristin Yarema. Le package de r茅mun茅ration comprend 436 080 options d'achat d'actions au prix d'exercice de 16,37 $ par action et 153 505 unit茅s d'actions restreintes (RSU).
Les r茅compenses, accord茅es le 28 juillet 2025, suivent un calendrier d'acquisition de droits sur quatre ans avec 25 % acquis apr猫s un an et les 75 % restants acquis au cours des p茅riodes suivantes. Les options d'achat ont une dur茅e de dix ans, tandis que les RSU seront acquises trimestriellement apr猫s une p茅riode initiale d'un an. Toutes les r茅compenses sont conditionn茅es 脿 la poursuite du service du Dr Yarema au sein de la soci茅t茅.
ImageneBio (Nasdaq: IMA), ein biotechnologisches Unternehmen in der klinischen Phase mit Schwerpunkt auf immunologischen und entz眉ndlichen Erkrankungen, hat seinem neuen CEO, Dr. Kristin Yarema, bedeutende Anreizaktien zugeteilt. Das Verg眉tungspaket umfasst 436.080 Aktienoptionen mit einem Aus眉bungspreis von 16,37 $ pro Aktie sowie 153.505 Restricted Stock Units (RSUs).
Die am 28. Juli 2025 gew盲hrten Zuteilungen unterliegen einem vierj盲hrigen Vesting-Zeitplan, wobei 25 % nach einem Jahr und die verbleibenden 75 % in den folgenden Perioden vesten. Die Aktienoptionen haben eine Laufzeit von zehn Jahren, w盲hrend die RSUs nach der anf盲nglichen einj盲hrigen Sperrfrist viertelj盲hrlich vesten. Alle Zuteilungen setzen die fortgesetzte T盲tigkeit von Dr. Yarema im Unternehmen voraus.
- None.
- Potential dilution from 589,585 new shares (options and RSUs combined)
SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA)聽(鈥淚mageneBio鈥�), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory (鈥淚&I鈥�) diseases, granted equity awards to Dr. Kristin Yarema, ImageneBio鈥檚 recently appointed Chief Executive Officer, on July 28, 2025 that were recommended by the Compensation Committee of its Board of Directors (the 鈥淏oard鈥�) and approved by the Board. The grant included (i) inducement stock options to purchase 436,080 shares of common stock; and (ii) inducement restricted stock units (鈥淩SUs鈥�) for 153,505 shares of common stock (together, the 鈥淚nducement Awards鈥�). The Inducement Awards were granted as inducements material to Dr. Yarema entering into employment with聽ImageneBio聽in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement stock options have an exercise price of聽
About ImageneBio, Inc.
ImageneBio is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological/autoimmune and inflammatory (鈥淚&I鈥�) diseases with differentiated clinical profiles. The company鈥檚 lead asset IMG-007, a nondepleting anti-OX40 monoclonal antibody, recently completed clinical trials in atopic dermatitis and alopecia areata. ImageneBio is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. For more information, please visit .
滨尘补驳别苍别叠颈辞听颁辞苍迟补肠迟
Anna Vardanyan
Brian Ritchie
FAQ
What equity compensation was granted to ImageneBio's (IMA) new CEO?
What is the vesting schedule for ImageneBio's (IMA) CEO equity awards?
What is the exercise price of ImageneBio's (IMA) CEO stock options?
Who is the new CEO of ImageneBio (IMA)?
When do ImageneBio's (IMA) CEO stock options expire?
